The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting.
about
Overexpression of LMO4 induces mammary hyperplasia, promotes cell invasion, and is a predictor of poor outcome in breast cancerPromotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy geneLive tissue intrinsic emission microscopy using multiphoton-excited native fluorescence and second harmonic generationTransforming growth factors-beta are not good biomarkers of chemopreventive efficacy in a preclinical breast cancer model system.Malignant myoepithelial cells are associated with the differentiated papillary structure and metastatic ability of a syngeneic murine mammary adenocarcinoma modelProteotypic classification of spontaneous and transgenic mammary neoplasmsAtm heterozygous deficiency enhances development of mammary carcinomas in p53 heterozygous knockout mice.Mouse models for breast cancerHost microenvironment in breast cancer development: extracellular matrix-stromal cell contribution to neoplastic phenotype of epithelial cells in the breastModels of breast cancer: is merging human and animal models the future?Models of breast cancer: quo vadis, animal modeling?Changes in gene expression during the development of mammary tumors in MMTV-Wnt-1 transgenic mice.Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ.Pathobiology of aging mice and GEM: background strains and experimental designThe Numb/p53 circuitry couples replicative self-renewal and tumor suppression in mammary epithelial cells.Scribble modulates the MAPK/Fra1 pathway to disrupt luminal and ductal integrity and suppress tumour formation in the mammary glandMRI accurately identifies early murine mammary cancers and reliably differentiates between in situ and invasive cancer: correlation of MRI with histologyPPARĪ“ activation acts cooperatively with 3-phosphoinositide-dependent protein kinase-1 to enhance mammary tumorigenesisPatient-derived tumour xenografts for breast cancer drug discoveryTIP30 interacts with an estrogen receptor alpha-interacting coactivator CIA and regulates c-myc transcriptionShcA signalling is essential for tumour progression in mouse models of human breast cancerColony-stimulating factor 1 promotes progression of mammary tumors to malignancyDeregulation of the Hippo pathway in mouse mammary stem cells promotes mammary tumorigenesis.Disruption of cyclin D1 nuclear export and proteolysis accelerates mammary carcinogenesisMultiparametric spectroscopic photoacoustic imaging of breast cancer development in a transgenic mouse model.Intravital microscopy: new insights into metastasis of tumors.The Mouse Tumor Biology Database: integrated access to mouse cancer biology data.Heterozygosity for a mutation in Brca1 or Atm does not increase susceptibility to ENU-induced mammary tumors in Apc(Min)/+ mice.From mice to humans: identification of commonly deregulated genes in mammary cancer via comparative SAGE studies.Transgenic mice with mammary gland targeted expression of human cortactin do not develop (pre-malignant) breast tumors: studies in MMTV-cortactin and MMTV-cortactin/-cyclin D1 bitransgenic miceHeterogeneity of mammary lesions represent molecular differencesA mouse model for luminal epithelial like ER positive subtype of human breast cancer.In vivo models in breast cancer research: progress, challenges and future directions.Influence of Hoxa5 on p53 tumorigenic outcome in mice.Wnt signaling activation and mammary gland hyperplasia in MMTV-LRP6 transgenic mice: implication for breast cancer tumorigenesis.Epithelial to mesenchymal transition and breast cancer.Dietary suppression of the mammary CD29(hi)CD24(+) epithelial subpopulation and its cytokine/chemokine transcriptional signatures modifies mammary tumor risk in MMTV-Wnt1 transgenic miceHER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancerPathways contributing to development of spontaneous mammary tumors in BALB/c-Trp53+/- mice.Molecular characterizations of Nop16 in murine mammary tumors with varying levels of c-Myc.
P2860
Q24529066-65781FD9-7AD4-42D7-BF88-E10AE249F0A4Q24617547-4D49FBB8-0E67-4D22-9D96-15CD460BEDA8Q24680802-17DD05FF-D1D5-4957-98F2-D3BAF0D97998Q24791032-47A8E21F-4DFE-4D23-AB13-43EDC55367B7Q24794341-1ED80829-DA37-4FC0-B990-309403B8D636Q24795869-4CCE552E-09F2-46E0-8D68-31353F30CA6BQ24796959-A4DE3D71-011D-41BD-B1DC-B860373E1E61Q24797754-AB3D7683-D1BE-4F18-B2BE-E2F37496C63EQ24803379-C341F460-45B2-4858-A041-84AB1CFAC45CQ24803657-95A00782-E316-4DA3-B83A-373AB575C724Q24803741-612D3CD5-0635-4251-9843-9BA587FAA443Q24812718-D9DC04B4-D709-45A8-9BB0-EFA1AFFC773CQ25257848-6F681D4D-DF6D-40A8-AD7F-249335C5E52CQ27008956-A559CD96-BF50-4FBA-8384-42A64B227623Q27309278-67EEA2DF-F4AC-4224-94AF-E2B1D7ED0986Q27315980-58FFBA00-F726-4F4B-ABE2-26FC543E1D5EQ27332108-1E578650-125E-4EF4-A75D-0403154E6336Q27437643-09971403-3B30-49F4-B254-72CD64A8B022Q28080046-5A16B0FC-01A2-4FDC-A42A-1CF8BF2ED224Q28255619-98F2CD9C-72D1-4B58-AC4A-ACC86CBBE0DFQ28590157-C40E2F6E-D839-4EA6-8B2D-2C453636EAFBQ29614312-A98D3C6F-51AB-4A32-AAF4-F4C8BA723D21Q30275987-F5E4C792-3D70-4789-BF62-DEC3A076512EQ30417762-F813F6FC-BB64-4099-BFB0-305498EAA202Q30429175-02D9AF82-4C27-46A2-9E70-09B28A30042FQ30497915-A5EE95B7-A6BE-49E9-9948-4882BAEA0881Q30986953-6FEE0FBD-9FB8-4A5C-93C0-F59BD85A4561Q31956444-5BDC6765-17EE-41A7-9616-1149A539BB24Q33208592-07D0D0A1-501B-4708-A6A9-D437971595A2Q33236460-DC3C59C0-DE17-433F-A4D2-F4CBE67839EEQ33265521-F4584842-8867-40EA-99D6-0B0F7AF5D0C2Q33299625-83C05C56-3CB2-4E44-B84E-897769D3385BQ33588117-E463A49A-6658-48DE-AAAB-E5776981E826Q33597261-51B68D1E-84BD-4210-BE77-18CB4F79D220Q33618690-315435B9-EFC4-4AF2-ACE9-33BF04B9D4F2Q33627118-F88DAE88-A384-4B0D-8DB8-849F0667B3C2Q33668304-A9916F74-BE81-49F3-9469-14F8B86897F8Q33694931-541F912B-08D9-4708-BB11-4220D78AA1A5Q33703779-DEED4316-2969-4853-B3E1-BEA31783CBE2Q33706956-8EE285B6-9A2A-43B2-9E1F-083E5932182B
P2860
The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting.
description
2000 nĆ® lÅ«n-bĆ»n
@nan
2000 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« ÕÕ„ÕæÖÕøÖÕ”ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
2000 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« ÖÕ„ÕæÖÕ¾Õ”ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
2000幓ć®č«ę
@ja
2000幓č«ę
@yue
2000幓č«ę
@zh-hant
2000幓č«ę
@zh-hk
2000幓č«ę
@zh-mo
2000幓č«ę
@zh-tw
2000幓č®ŗę
@wuu
name
The mammary pathology of genet ...... ns from the Annapolis meeting.
@ast
The mammary pathology of genet ...... ns from the Annapolis meeting.
@en
type
label
The mammary pathology of genet ...... ns from the Annapolis meeting.
@ast
The mammary pathology of genet ...... ns from the Annapolis meeting.
@en
prefLabel
The mammary pathology of genet ...... ns from the Annapolis meeting.
@ast
The mammary pathology of genet ...... ns from the Annapolis meeting.
@en
P2093
P356
P1433
P1476
The mammary pathology of genet ...... ns from the Annapolis meeting.
@en
P2093
Cardiff RD
Gusterson BA
Hennighausen L
Tavassoli FA
P2888
P304
P356
10.1038/SJ.ONC.1203277
P407
P577
2000-02-01T00:00:00Z
P5875
P6179
1043238002